Tenderwize
Wróć do wyszukiwania

Open-House contract for Bimatoprost/Timolol eye drops

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 126 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of pharmaceutical rebate contracts under Section 130a(8) SGB V for Bimatoprost/Timolol eye drops in single-dose pipettes.
  • Open-House model with uniform terms; no individual contract negotiations.
Pokaż pełne podsumowanie

This is a German Open-House pharmaceutical supply arrangement for Bimatoprost/Timolol eye drops in single-dose pipettes, led by Techniker Krankenkasse with HEK as a participating buyer. It is not a classic award procedure: no individual negotiations, no exclusivity, and contract entry is possible throughout the contract period if eligibility conditions are met. The notice and XML indicate electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post. No contract value is stated.

Ryzyka

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Bidder must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Bidder must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Bidder must hold a valid marketing authorisation for the contract medicinal product(s) or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House contract for Bimatoprost/Timolol eye drops

Open-House pharmaceutical rebate contract for the fixed medicinal product combination Bimatoprost/Timolol in the form of single-dose eye drops. Scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Dec 29, 2026

Szczegóły zamówienia

Data publikacji
17 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
702294-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3